vs
PagerDuty, Inc.（PD）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是PagerDuty, Inc.的1.1倍（$139.1M vs $124.5M），PagerDuty, Inc.净利率更高（129.7% vs 20.6%，领先109.1%），VERACYTE, INC.同比增速更快（21.5% vs 4.7%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 5.9%）
PagerDuty是一家美国云计算企业，主打面向IT运维部门的SaaS事件管理平台，可帮助企业实时响应运维异常、快速定位并处理故障，保障业务系统稳定运行，目前已成为全球IT运维领域广受认可的数字化解决方案服务商。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
PD vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.1倍
$124.5M
营收增速更快
VCYT
高出16.8%
4.7%
净利率更高
PD
高出109.1%
20.6%
两年增速更快
VCYT
近两年复合增速
5.9%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $124.5M | $139.1M |
| 净利润 | $161.6M | $28.7M |
| 毛利率 | 85.3% | 72.7% |
| 营业利润率 | 6.5% | 16.3% |
| 净利率 | 129.7% | 20.6% |
| 营收同比 | 4.7% | 21.5% |
| 净利润同比 | 2827.7% | — |
| 每股收益（稀释后） | $1.69 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PDVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $124.5M | $140.6M | ||
| Q3 25 | $123.4M | $131.9M | ||
| Q2 25 | $119.8M | $130.2M | ||
| Q1 25 | $121.4M | $114.5M | ||
| Q4 24 | $118.9M | $118.6M | ||
| Q3 24 | $115.9M | $115.9M | ||
| Q2 24 | $111.2M | $114.4M |
净利润PDVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | $161.6M | $41.1M | ||
| Q3 25 | $9.6M | $19.1M | ||
| Q2 25 | $-7.2M | $-980.0K | ||
| Q1 25 | $-8.8M | $7.0M | ||
| Q4 24 | $-5.9M | $5.1M | ||
| Q3 24 | $-10.9M | $15.2M | ||
| Q2 24 | $-17.1M | $5.7M |
毛利率PDVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | 85.3% | 72.5% | ||
| Q3 25 | 84.6% | 69.2% | ||
| Q2 25 | 84.0% | 69.0% | ||
| Q1 25 | 83.6% | 69.5% | ||
| Q4 24 | 83.0% | 66.4% | ||
| Q3 24 | 82.7% | 68.2% | ||
| Q2 24 | 82.6% | 68.1% |
营业利润率PDVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 6.5% | 26.4% | ||
| Q3 25 | 2.9% | 17.4% | ||
| Q2 25 | -8.6% | -4.0% | ||
| Q1 25 | -9.6% | 2.5% | ||
| Q4 24 | -8.7% | 3.5% | ||
| Q3 24 | -13.8% | 10.4% | ||
| Q2 24 | -19.5% | 4.0% |
净利率PDVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | 129.7% | 29.3% | ||
| Q3 25 | 7.8% | 14.5% | ||
| Q2 25 | -6.0% | -0.8% | ||
| Q1 25 | -7.2% | 6.2% | ||
| Q4 24 | -5.0% | 4.3% | ||
| Q3 24 | -9.4% | 13.1% | ||
| Q2 24 | -15.4% | 5.0% |
每股收益（稀释后）PDVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $1.69 | $0.50 | ||
| Q3 25 | $0.10 | $0.24 | ||
| Q2 25 | $-0.07 | $-0.01 | ||
| Q1 25 | $-0.12 | $0.09 | ||
| Q4 24 | $-0.07 | $0.07 | ||
| Q3 24 | $-0.14 | $0.19 | ||
| Q2 24 | $-0.26 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $547.8M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $320.5M | $1.3B |
| 总资产 | $1.0B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PDVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $547.8M | $362.6M | ||
| Q3 25 | $567.9M | $315.6M | ||
| Q2 25 | $597.1M | $219.5M | ||
| Q1 25 | $570.8M | $186.1M | ||
| Q4 24 | $542.2M | $239.1M | ||
| Q3 24 | $599.3M | $274.1M | ||
| Q2 24 | $592.8M | $235.9M |
总债务PDVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $484.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PDVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $320.5M | $1.3B | ||
| Q3 25 | $180.7M | $1.3B | ||
| Q2 25 | $145.7M | $1.2B | ||
| Q1 25 | $129.8M | $1.2B | ||
| Q4 24 | $111.6M | $1.2B | ||
| Q3 24 | $164.7M | $1.2B | ||
| Q2 24 | $174.0M | $1.1B |
总资产PDVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $891.5M | $1.4B | ||
| Q2 25 | $926.8M | $1.3B | ||
| Q1 25 | $927.3M | $1.3B | ||
| Q4 24 | $866.8M | $1.3B | ||
| Q3 24 | $916.0M | $1.3B | ||
| Q2 24 | $924.0M | $1.2B |
负债/权益比PDVCYT
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.73× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $24.8M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $24.1M | — |
| 自由现金流率自由现金流/营收 | 19.3% | — |
| 资本支出强度资本支出/营收 | 0.6% | — |
| 现金转化率经营现金流/净利润 | 0.15× | 1.23× |
| 过去12个月自由现金流最近4个季度 | $117.6M | — |
8季度趋势，按日历期对齐
经营现金流PDVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $24.8M | $52.6M | ||
| Q3 25 | $34.0M | $44.8M | ||
| Q2 25 | $30.7M | $33.6M | ||
| Q1 25 | $31.4M | $5.4M | ||
| Q4 24 | $22.1M | $24.5M | ||
| Q3 24 | $35.8M | $30.0M | ||
| Q2 24 | $28.6M | $29.6M |
自由现金流PDVCYT
| Q1 26 | — | — | ||
| Q4 25 | $24.1M | $48.8M | ||
| Q3 25 | $33.1M | $42.0M | ||
| Q2 25 | $30.2M | $32.3M | ||
| Q1 25 | $30.3M | $3.5M | ||
| Q4 24 | $21.5M | $20.4M | ||
| Q3 24 | $35.1M | $27.7M | ||
| Q2 24 | $28.2M | $26.8M |
自由现金流率PDVCYT
| Q1 26 | — | — | ||
| Q4 25 | 19.3% | 34.7% | ||
| Q3 25 | 26.8% | 31.8% | ||
| Q2 25 | 25.2% | 24.8% | ||
| Q1 25 | 24.9% | 3.1% | ||
| Q4 24 | 18.1% | 17.2% | ||
| Q3 24 | 30.3% | 23.9% | ||
| Q2 24 | 25.4% | 23.4% |
资本支出强度PDVCYT
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 2.7% | ||
| Q3 25 | 0.7% | 2.1% | ||
| Q2 25 | 0.4% | 1.0% | ||
| Q1 25 | 0.9% | 1.6% | ||
| Q4 24 | 0.5% | 3.5% | ||
| Q3 24 | 0.5% | 1.9% | ||
| Q2 24 | 0.4% | 2.4% |
现金转化率PDVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | 0.15× | 1.28× | ||
| Q3 25 | 3.55× | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
